The Clorox Company (NYSE:CLX) Stock Holdings Lifted by Skandinaviska Enskilda Banken AB publ

Key Points

• Skandinaviska Enskilda Banken AB increased its holdings in The Clorox Company by 167.9%, owning approximately 0.09% of the company, valued at $17 million after acquiring additional shares during the first quarter.
• The Clorox Company reported earnings per share of $1.45 for the last quarter, missing estimates by $0.12, and experienced an 8% decline in revenue compared to the previous year.
• Analysts have Set a range of target prices for Clorox, with some major cuts, leading to a current consensus target price of $144.83 and an overall rating of "Hold" from equity research analysts.

Skandinaviska Enskilda Banken AB publ raised its position in The Clorox Company (NYSE:CLX - Free Report) by 167.9% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 115,502 shares of the company's stock after purchasing an additional 72,395 shares during the quarter. Skandinaviska Enskilda Banken AB publ owned approximately 0.09% of Clorox worth $17,008,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Redwood Park Advisors LLC bought a new position in shares of Clorox during the 4th quarter worth about $26,000. Wood Tarver Financial Group LLC bought a new position in shares of Clorox during the 4th quarter worth approximately $31,000. GKV Capital Management Co. Inc. bought a new position in shares of Clorox during the 4th quarter worth approximately $32,000. Aster Capital Management DIFC Ltd bought a new position in shares of Clorox during the 4th quarter worth approximately $33,000. Finally, GW&K Investment Management LLC lifted its position in shares of Clorox by 239.1% during the 1st quarter. GW&K Investment Management LLC now owns 295 shares of the company's stock worth $43,000 after buying an additional 208 shares during the period. Hedge funds and other institutional investors own 78.53% of the company's stock.

Clorox Trading Down 0.5%

CLX stock opened at $130.80 on Friday. The company has a market cap of $16.12 billion, a P/E ratio of 23.48, a PEG ratio of 3.46 and a beta of 0.51. The Clorox Company has a twelve month low of $117.35 and a twelve month high of $171.37. The company has a quick ratio of 0.44, a current ratio of 0.74 and a debt-to-equity ratio of 13.07. The business has a fifty day moving average of $126.77 and a 200-day moving average of $140.29.

Clorox (NYSE:CLX - Get Free Report) last released its earnings results on Monday, May 5th. The company reported $1.45 earnings per share for the quarter, missing analysts' consensus estimates of $1.57 by ($0.12). The firm had revenue of $1.67 billion for the quarter, compared to the consensus estimate of $1.74 billion. Clorox had a return on equity of 324.23% and a net margin of 9.89%. The company's revenue was down 8.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.71 EPS. As a group, equities research analysts expect that The Clorox Company will post 7.15 EPS for the current year.

Insider Activity at Clorox

In related news, Director Pierre R. Breber acquired 4,000 shares of the firm's stock in a transaction that occurred on Wednesday, May 7th. The stock was acquired at an average cost of $136.57 per share, with a total value of $546,280.00. Following the completion of the purchase, the director directly owned 4,000 shares in the company, valued at approximately $546,280. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.57% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the company. Evercore ISI set a $140.00 target price on Clorox and gave the stock an "underperform" rating in a research report on Tuesday, May 6th. Morgan Stanley cut their target price on Clorox from $165.00 to $150.00 and set an "equal weight" rating for the company in a research report on Tuesday, May 6th. UBS Group cut their target price on Clorox from $150.00 to $134.00 and set a "neutral" rating for the company in a research report on Thursday, July 17th. Citigroup restated a "neutral" rating and set a $135.00 target price (down previously from $140.00) on shares of Clorox in a research report on Tuesday, July 15th. Finally, Jefferies Financial Group cut their price objective on Clorox from $167.00 to $145.00 and set a "buy" rating for the company in a research report on Thursday, June 26th. Three investment analysts have rated the stock with a sell rating, ten have given a hold rating and one has given a buy rating to the company. According to data from MarketBeat, Clorox presently has a consensus rating of "Hold" and a consensus target price of $144.83.

Clorox Company Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.